Global Regenerative Medicine Market to Grow at a CAGR of 11.7% over the Forecast Period of 2024-2032

The global regenerative medicine market is being driven by the rising incidences of bone replacement and other surgeries and the rapid advancement in the field of tissue engineering. The rise in the number of clinical trials, supported by both the government and private organisations, is further contributing to the market growth.

North America dominates the industry, accounting for a significant share in the global regenerative medicine market. The industry growth in the region can be attributed to the increased penetration of the key players, and the availability of advanced research institutes and technologies. Researchers supported by the National Institutes of Health (NIH), a component of the U.S. Department of Health and Human Services, developed a clinical-grade stem cell line in 2016, having the ability to boost the advance of new medical applications and cell-based therapies for diseases like Alzheimer’s disease, Parkinson’s disease, spinal cord injury, diabetes, and muscular dystrophy. The Asia Pacific is expected be one of the major emerging markets for regenerative medicines over the forecast period owing to the rising population and increased government expenditure in the research sector.

Continuous development in the field of minimally invasive surgical (MIS) procedures by the manufacturers is leading to the increased prevalence of such surgeries, which will further drive the demand for regenerative medicines. In September 2020, Integra LifeSciences Holdings Corporation (NASDAQ: IART), a global leader in medical technology, announced the acquisition of Rebound Therapeutics, manufacturers of single-use medical devices with integrated optics and illumination capability, providing minimally invasive access for therapeutic and diagnostic use in neurosurgery. This acquisition will allow Integra to further develop innovative products to address unmet needs in neurosurgery, thus helping surgeons improve the standard of care, and in turn, boost the sales of regenerative medicines. Such developments are expected to aid the growth of the regenerative medicine industry globally in the forecast period.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Market Breakup by Technology, Application, and Regions:

• By technology, the global regenerative medicine industry can be divided into stem cell therapy, biomaterial, and tissue engineering, among others.

• On the basis of application, the industry is categorised into bone graft substitutes, osteoarticular diseases, dermatology, cardiovascular, central nervous system, and others. 

• Region-wise, the global regenerative medicine market can be divided into North America, the Asia Pacific, Europe, Latin America, and the Middle East and Africa.

Key Findings of the Report:

• The global regenerative medicine market is being driven by the rapid advancement in the field of tissue engineering and molecular biology. 

• Rising investments by the government agencies to develop healthcare infrastructures, further supporting R&D in the field of regenerative medicine, is leading to the industry growth globally.

• The growing prevalence of osteoarticular and cardiovascular diseases, along with bone grafting and surgical procedures, is providing further impetus to the industry. 

• The growing investment and increased R&D by the key players to develop enhanced solutions are aiding the industry further.

Key Offerings of the Report:

• The EMR report gives an analysis of the global regenerative medicine market for the periods (2018-2023) and (2024-2032). 

• The report offers historical (2018-2023) and forecast (2024-2032) market trends for the technology, applications, and regional markets for the global regenerative medicine market.

• It also provides an assessment of the industry based on the Porter’s Five Forces model, along with a SWOT analysis.

The major players in the global regenerative medicine market are Novartis AG, Vericel, Mimedx Group, Integra Lifesciences, Stryker, Wright Medical, Spark Therapeutics, Osiris Therapeutics, Kite Pharma (Subsidiary of Gilead Sciences), and Organogenesis, among others. The comprehensive report by EMR looks into the market share, capacity, and latest developments like mergers and acquisitions, plant turnarounds, and capacity expansions of the major players.

About Us:

Expert Market Research (EMR) is a leading market research and business intelligence company, ensuring its clients remain at the vanguard of their industries by providing them with exhaustive and actionable market data through its syndicated and custom market reports, covering over 15 major industry domains. The company's expansive and ever-growing database of reports, which are constantly updated, includes reports from industry verticals like chemicals and materials, food and beverages, energy and mining, technology and media, consumer goods, pharmaceuticals, agriculture, and packaging.

EMR leverages its state-of-the-art technological and analytical tools, along with the expertise of its highly skilled team of over a 100 analysts and more than 3000 consultants, to help its clients, ranging from Fortune 1000 companies to small and medium sized enterprises, easily grasp the expansive industry data and help them in formulating market and business strategies, which ensure that they remain ahead of the curve.

Contact Us:

Expert Market Research
Website: www.expertmarketresearch.com
Email: sales@expertmarketresearch.com
US & Canada Phone no: +1-415-325-5166
UK Phone no: +44-702-402-5790

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.